Stay updated on Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.

Latest updates to the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page
- Check2 days agoChange DetectedThe page shows a new revision label, updating from v3.5.3 to v3.5.4. This indicates an underlying platform or template update without altering the study details.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision label was updated from v3.5.2 to v3.5.3, indicating a minor update to the page template. This update does not alter the study details or data presented on the page.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedChangelog updated with Revision: v3.5.2 added and Revision: v3.5.0 removed.SummaryDifference0.1%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor metadata update with no changes to study information.SummaryDifference0.1%

- Check74 days agoChange DetectedAdds explicit institution names (Moffitt Cancer Center and Research Institute) and a 'Helpful Links Provided by' section to the study page, clarifying sponsorship and related resources.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Ibrutinib Combo in CRC Clinical Trial page.